Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden saysnews2025-12-09T12:30:22+00:00December 9th, 2025|Endpoints News|
Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiarynews2025-12-09T12:01:17+00:00December 9th, 2025|Endpoints News|
Biosecure Act appears headed for final passage in defense billnews2025-12-08T20:17:06+00:00December 8th, 2025|Endpoints News|
FDA misses PDUFA review deadline for Agios’ thalassemia drugnews2025-12-08T18:08:34+00:00December 8th, 2025|Endpoints News|
#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AMLnews2025-12-08T15:45:18+00:00December 8th, 2025|Endpoints News|
Merck outbid three competitors in Cidara acquisition — new filingnews2025-12-08T14:41:45+00:00December 8th, 2025|Endpoints News|
Mirum to pay $620M for Bluejay and its hepatitis D antibodynews2025-12-08T13:00:20+00:00December 8th, 2025|Endpoints News|
Apple Tree Partners scores legal win against alleged holdout Russian investornews2025-12-06T11:37:53+00:00December 6th, 2025|Endpoints News|
Bristol Myers expands Breyanzi approval to marginal zone lymphomanews2025-12-05T19:17:02+00:00December 5th, 2025|Endpoints News|
ACIP drops universal hepatitis B birth dose recommendationnews2025-12-05T16:52:18+00:00December 5th, 2025|Endpoints News|
